ANALYSIS: With an Obermatt 360° View of 76 (better than 76% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Cytek Biosciences are very positive. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators above average for Cytek Biosciences. The consolidated Value Rank has an attractive rank of 78, which means that the share price of Cytek Biosciences is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 78% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 81, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. The company is also safely financed with a Safety Rank of 72. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of only 13. Professional investors are more confident in 87% other stocks. ...read more